Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study DOI Creative Commons
Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown

Опубликована: Июнь 2, 2022

ABSTRACT Background Ongoing outbreaks of COVID-19 are driven by waning immunity following primary immunizations and emergence new SARS-CoV-2 variants which escape vaccine-induced neutralizing antibodies. It has been suggested that heterologous boosters could enhance potentially maintain population immunity. Methods We assessed immunogenicity reactogenicity booster doses different formulations alum-adjuvanted SCB-2019 vaccine (9 μg with or without CpG-1018 adjuvant, 30 CpG-1018) in Brazilian adults primed ChAdOx1-S vector vaccine. S-protein antibodies ACE2-binding inhibition were measured ELISA on Days 1, 15 29. Participants self-reported solicited adverse events reactions. Results All increased ACE2 binding to a greater extent than ChAdOx1-S. After SCB-2019+CpG+alum titers against wild-type significantly higher after 29, as strain Beta, Gamma, Delta, Omicron variants. Boosting was well tolerated no vaccine-related serious severe events. Conclusions ChAdOx1-S-primed induced levels homologous booster, highest responses being the formulation.

Язык: Английский

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19 DOI Creative Commons
Georg Behrens, Joana Barros‐Martins, Anne Cossmann

и другие.

Nature Communications, Год журнала: 2022, Номер 13(1)

Опубликована: Авг. 18, 2022

Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) has been reported to be superior in inducing protective immunity compared repeated application of the same vaccine. However, data comparing decline after homologous and heterologous as well effects third ChAd/BNT are lacking. Here we show longitudinal monitoring ChAd/ChAd (n = 41) 88) vaccinated individuals impact BNT. The greatly augments waning anti-spike IgG but results only moderate increase spike-specific CD4 + CD8 T cell numbers both groups, frequencies already present second group. More importantly, efficiently restores neutralizing antibody responses against Alpha, Beta, Gamma, Delta variants virus, activity B.1.1.529 (Omicron) variant remains severely impaired. In summary, inferior SARS-CoV-2 specific immune following can compensated BNT vaccination, which might influence choice type for subsequent boosts.

Язык: Английский

Процитировано

38

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines DOI Creative Commons
Moe H. Kyaw, Júlia Spinardi, Ling Zhang

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(1)

Опубликована: Янв. 2, 2023

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred heterologous booster regimens informs alternative strategies that enable programmatic resilience can catalyze vaccine confidence coverage. Inactivated vaccines are among most widely used worldwide. This review synthesizes available evidence identified as May 26, 2022, on safety, immunogenicity, effectiveness a BNT162b2 (Pfizer-BioNTech) mRNA dose after an inactivated series, to help protect against COVID-19. Evidence showed BNT16b2 enhances immunogenicity improves COVID-19, no new safety concerns were with series combinations.

Язык: Английский

Процитировано

11

Enhanced Production of Lipid Mediators in Plasma and Activation of DNA Damage Pathways in PBMCs Are Correlated With the Severity of Ancestral SARSCoV‐2 Infection DOI

Jeffrey Tomalka,

Anna H. Owings, Michelle Galeas‐Pena

и другие.

The FASEB Journal, Год журнала: 2025, Номер 39(9)

Опубликована: Май 5, 2025

ABSTRACT Many questions remain unanswered regarding the implication of genetics and lipid metabolites with severe SARS‐CoV‐2 infections. We performed bulk RNA‐seq a total fatty acid panel analysis on PBMCs plasma collected from 10 infected uninfected patients. Univariate comparison using Mann–Whitney U ‐test revealed that six were significantly increased in COVID‐19 patients, including mediators arachidonic (AA) eicosapentaenoic (EPA), which both give rise to eicosanoids. Key lipids implicated inflammation, AA EPA, along acids DHA DPA, positively correlated WHO disease severity score. Analysis our dataset demonstrated distinct transcriptional profiles leading segregation patients based Ontology, KEGG, Reactome identified several key pathways nodes enriched for genes related innate immunity, interactions between lymphoid nonlymphoid cells, interleukin signaling, subsequent DNA damage pathways. EPA levels heightened cell cycling observed high studied gene expression nasopharyngeal swabs 58 healthy participants eicosanoid synthesis, such as alox5, alox12, alox15B, specifically up‐regulated score types nasopharynx, especially goblet cells across different viral variants (Deta Omicron). Using published nasal scRNA‐seq datasets we evaluated ALOX5 , ALOX15, ALOX15B groups. Altogether, study highlights fact increase specific inflammation required their synthesis infection.

Язык: Английский

Процитировано

0

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study DOI Creative Commons
Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz

и другие.

Open Forum Infectious Diseases, Год журнала: 2022, Номер 9(8)

Опубликована: Авг. 1, 2022

Ongoing outbreaks of coronavirus disease 2019 (COVID-19) are driven by waning immunity following primary immunizations and emergence new severe acute respiratory syndrome 2 (SARS-CoV-2) variants that escape vaccine-induced neutralizing antibodies. It has been suggested heterologous boosters could enhance potentially maintain population immunity. We assessed the immunogenicity reactogenicity booster doses different formulations aluminium hydroxide-adjuvanted SCB-2019 vaccine (9 μg SCB-2019, with or without CpG-1018 adjuvant, 30 CpG-1018) in Brazilian adults primed ChAdOx1-S vector vaccine. S-protein antibodies ACE2-binding inhibition were measured enzyme-linked immunosorbent assay (ELISA) on days 1, 15, 29. Participants self-reported solicited adverse events reactions. All increased ELISA ACE2 binding to a greater extent than ChAdOx1-S. After + CpG hydroxide, titers against wild-type significantly higher after 15 29, as strain Beta, Gamma, Delta, Omicron variants. Boosting was well tolerated, no vaccine-related serious events. ChAdOx1-S-primed induced levels SARS-CoV-2 homologous booster, highest responses being 30-μg hydroxide formulation. NCT05087368.

Язык: Английский

Процитировано

11

Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously DOI Open Access
Lairun Jin, Rong Tang, Shipo Wu

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown

Опубликована: Июль 28, 2022

Abstract Background Heterologous orally administered adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in individuals who were primed with two-dose CoronaVac (an inactivated SARS-CoV-2 vaccine, by Sinovac) previously, has been reported to be safe and highly immunogenic within 28 days post-boosting. However, antibody persistence safety up 6 months of this regimen are not yet. Methods This is a randomized, open label, single-center trial on immunogenicity heterologous boost immunization an aerosolised Ad5-nCoV vs. homologous after priming Chinese adults aged 18 years older ( NCT05043259 ). We followed the participants trial, including 140 low-dose group, 139 high-dose group for months. Neutralising antibodies (NAbs) against live wild-type virus omicron variant, receptor-binding domain (RBD)-specific IgG detected serum samples collected at days, 3 months, booster dose. Serious adverse events (SAEs) documented till month 6. Results The immunisation groups had NAb GMTs 1937.3 [95% CI 1466.9, 2558.4] 1350.8 952.6, 1915.3], which 26.4 folds 18.4 higher than that did (73.5 52.3, 103.3]) days. 530.1 (95% 412.5, 681.1) 457.6 (95%CI 349.4, 599.2), 26.0 22.4 (20.4 [95%CI 14.3, 29.1]) respectively. At 312.9 237.7, 411.8) 251.1 178.2, 354.0), 30.1 24.1 (10.4 7.8, 14.0]), Additionally, variant 52.0 37.2, 72.6) 23.1 15.7, 33.9) 27.9 18.8, 41.3) 23.3 16.2, 33.3) 16.0 10.9, 23.5) 12.0 8.5, 16.8) nearly all no detectable NAbs either or No vaccine-related SAEs observed. Conclusions These data suggested following was persistently more three-dose CoronaVac, although immune responses waned over time.

Язык: Английский

Процитировано

10

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant DOI Creative Commons
Natalie Heinen,

Corinna Marheinecke,

Clara Bessen

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Дек. 21, 2022

With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants Concern (VOCs), vaccination studies that elucidate efficiency and effectiveness a campaign are critical to assess durability protective immunity provided by vaccines. SARS-CoV-2 vaccines have been found induce robust humoral cell-mediated in individuals vaccinated with homologous regimens. Recent also suggest improved immune response against when heterologous strategies employed. Yet, few data exist on extent which prime-boost-boost vaccinations two different vaccine platforms an impact T responses special emphasis currently dominantly circulating Omicron strain. In this study, we collected serum peripheral blood mononuclear cells (PBMCs) from 57 study participants median 35-year old’s working health care field, who received Neutralization assays revealed but decreased neutralization VOC, including BA.1 BA.4/5, compared WT all groups increased binding neutralizing antibodies titers mRNA participants. By investigating cytokine production, prime-boost-boost-vaccination induces CD4 + CD8 cells. Collectively, our results indicate cell mediated participants, might serve as guide for policy decisions.

Язык: Английский

Процитировано

7

SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost DOI
Olivera Lijeskić, Neda Bauman, Miloš Marković

и другие.

Vaccine, Год журнала: 2024, Номер 42(7), С. 1665 - 1672

Опубликована: Фев. 10, 2024

Язык: Английский

Процитировано

1

Humoral Immune Response to CoronaVac in Turkish Adults DOI Creative Commons
Yasemin Coşgun,

Nergis Emanet,

Ayten Öz Kamiloglu

и другие.

Vaccines, Год журнала: 2023, Номер 11(2), С. 216 - 216

Опубликована: Янв. 18, 2023

While most approved vaccines are based on the viral spike protein or its immunogenic regions, inactivated whole-virion (e.g., CoronaVac) contain additional antigens that may enhance protection. This study analyzes short-term humoral responses against SARS-CoV-2 (S1) and nucleocapsid (NCP) in 50 Turkish adults without previous infection after CoronaVac immunization. Samples were collected before vaccination (t0), 28–29 days first vaccine dose prior to second (t1), as well 14–15 (t2). Anti-S1 IgG IgA anti-NCP quantified using ELISA. At t1, seroconversion rates for anti-S1 IgG, 30.0%, 28.0% 4.0%, respectively, increasing significantly 98.0%, 78.0% 40.0% at t2. The median (t2) was below positivity cut-off, while medians positive. levels strongly correlated with (rs = 0.767, p < 0.001) 0.683, 0.001). In conclusion, two doses induced significant increases antibodies S1 NCP. Despite strong correlations between antibody concentrations, of S1-specific exceed those NCP-specific early weeks dose.

Язык: Английский

Процитировано

1

Cellular and Humoral Immune Responses to Vaccination for COVID-19 Are Negatively Impacted by Senescent T Cells: A Case Report DOI Creative Commons
Eliane Aparecida Rosseto-Welter, Silvia Sanches Rodrigues, Amanda Braga Figueiredo

и другие.

Vaccines, Год журнала: 2023, Номер 11(4), С. 840 - 840

Опубликована: Апрель 14, 2023

Herein, we aimed to follow up on the cellular and humoral immune responses of a group individuals who initially received CoronaVac vaccine, followed by booster with Pfizer vaccine.Blood samples were collected: before 30 days after first dose; 30, 90, 180 second dose, also 20 vaccine.Whilst positivity gamma interferon-type response increased neutralizing IgG antibody levels only raised drop in these 90 days. The vaccine elicited robust response. A higher number double-negative senescent T cells, as well pro-inflammatory cytokines found participants lower responses.CoronaVac an early response, which dropped dose. significantly enhanced responses. Furthermore, systemic status was volunteers presented could putatively impair vaccination.

Язык: Английский

Процитировано

1

Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study DOI Creative Commons
Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown

Опубликована: Июнь 2, 2022

ABSTRACT Background Ongoing outbreaks of COVID-19 are driven by waning immunity following primary immunizations and emergence new SARS-CoV-2 variants which escape vaccine-induced neutralizing antibodies. It has been suggested that heterologous boosters could enhance potentially maintain population immunity. Methods We assessed immunogenicity reactogenicity booster doses different formulations alum-adjuvanted SCB-2019 vaccine (9 μg with or without CpG-1018 adjuvant, 30 CpG-1018) in Brazilian adults primed ChAdOx1-S vector vaccine. S-protein antibodies ACE2-binding inhibition were measured ELISA on Days 1, 15 29. Participants self-reported solicited adverse events reactions. Results All increased ACE2 binding to a greater extent than ChAdOx1-S. After SCB-2019+CpG+alum titers against wild-type significantly higher after 29, as strain Beta, Gamma, Delta, Omicron variants. Boosting was well tolerated no vaccine-related serious severe events. Conclusions ChAdOx1-S-primed induced levels homologous booster, highest responses being the formulation.

Язык: Английский

Процитировано

0